Acadia Healthcare Appoints Daniel Cancelmi to Board of Directors; Wade D. Miquelon Announces Retirement

Summary of Key Points for Investors

• Appointment of Daniel Cancelmi: Acadia Healthcare has appointed Daniel Cancelmi, a highly experienced healthcare finance executive, to its Board of Directors effective immediately.
• Retirement of Wade D. Miquelon: Long-serving director Wade D. Miquelon will not stand for re-election at the 2026 Annual Meeting, marking a significant change in board composition.
• Strategic Focus: The company remains committed to disciplined growth, expanding access to behavioral healthcare, improving clinical outcomes, and driving operational efficiency.
• Comprehensive Search and Shareholder Engagement: The board’s search for Cancelmi included engagement with Khrom Capital and assistance from a nationally recognized executive search firm.
• Financial and Legal Advisors: Goldman Sachs and J.P. Morgan are advising Acadia financially, while Kirkland & Ellis LLP is providing legal counsel.
• Forward-Looking Statements: The company includes a caution regarding risks and uncertainties, including integration challenges, regulatory changes, and impacts from recent Medicaid legislation.

Detailed Analysis for Investors

Board Appointment: Daniel Cancelmi

Acadia Healthcare has made a significant leadership addition by appointing Daniel Cancelmi to its Board of Directors. Cancelmi brings over 30 years of healthcare finance and operational experience, most recently serving as Executive Vice President and Chief Financial Officer at Tenet Healthcare Corporation. During his tenure as CFO, Cancelmi was instrumental in transforming Tenet’s performance, growing revenue to nearly \$21 billion in 2023, and overseeing a robust balance sheet. He also played a central role in Tenet’s portfolio transformation, including major acquisitions such as United Surgical Partners International (USPI) and over 100 ambulatory surgery centers from SurgCenter Development, as well as executing various hospital divestitures. Cancelmi holds a Bachelor of Science from Duquesne University, is a member of its Board of Directors, and is a certified public accountant licensed in Texas and Florida.

The addition of Cancelmi is expected to bolster Acadia’s strategic execution, particularly in financial leadership, operational efficiency, and healthcare services expertise. His extensive experience could be highly influential as Acadia pursues continued growth and value creation for shareholders.

Retirement of Wade D. Miquelon

Acadia also announced that director Wade D. Miquelon will retire and not stand for re-election at the 2026 Annual Meeting. Miquelon has contributed significantly to the company, providing strategic guidance during its expansion and efforts to increase access to care. His departure marks a transition in board leadership, but he will continue to offer strategic insights through his planned retirement period. The company expresses gratitude for his years of service and guidance.

Strategic Direction and Growth

Acadia’s board, led by Chairman Reeve B. Waud, emphasized its ongoing focus on disciplined growth, expanding access to behavioral healthcare, improving clinical outcomes, and operational efficiency. Cancelmi’s appointment, following a thorough search and shareholder engagement, is seen as critical to advancing these priorities.

Company Overview and Scale

As of December 31, 2025, Acadia operated a network of 277 behavioral healthcare facilities with over 12,500 beds across 40 states and Puerto Rico. The company employs approximately 25,000 people and serves more than 84,000 patients daily, making it the largest stand-alone behavioral healthcare provider in the U.S. Services are offered in settings such as inpatient psychiatric hospitals, specialty treatment facilities, residential centers, and outpatient clinics.

Forward-Looking Statements and Risks

Acadia cautions investors that its statements involve risks and uncertainties, including integration challenges with acquisitions, the ability to expand services and improve efficiencies, potential reductions in payments from government and commercial payors (notably due to significant changes in Medicaid introduced by the One Big Beautiful Bill Act, OBBBA), regulatory actions, cybersecurity risks, and disruptions in the U.S. economy or healthcare industry. The OBBBA, enacted on July 4, 2025, introduces new Medicaid financing mechanisms and work/community engagement requirements, which could impact patient volumes and financial performance.

The company’s ability to generate sufficient cash flow, manage labor and supply chain costs, and adapt to changing competition and client preferences are all highlighted as factors that could materially affect future results and share value.

Advisory and Investor Contacts

Investors and media are advised to contact Acadia’s financial advisors (Goldman Sachs, J.P. Morgan), legal advisor (Kirkland & Ellis LLP), or Investor Relations (Patrick Feeley, Senior Vice President) for further information.

Implications for Shareholders

• The appointment of a prominent finance executive to the board may signal renewed focus on financial discipline and growth, potentially influencing share value positively.
• Miquelon’s retirement and ongoing strategic guidance during transition could impact investor sentiment.
• Risks associated with regulatory changes (especially Medicaid/OBBBA), integration of acquisitions, and operational challenges are highlighted as potential negative drivers for share price.
• Continued engagement with major financial and legal advisors suggests active strategic management and possible future corporate actions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should review Acadia Healthcare’s filings with the Securities and Exchange Commission and consult their financial advisors before making investment decisions.

View Acadia Healthcare Company, Inc. Historical chart here